Fig. 5.

IL-6 sensitizes breast cancer cells to low levels of testosterone. a QPCR analysis of Fkbp5 expression in MCF7 cells treated with varying doses of testosterone in the presence or absence of IL-6. b QPCR analysis of Fkbp5 expression in MCF7 cells treated with low (0.1 nM) or high (10 nM) testosterone in the presence or absence of IL-6, and co-treated either with fulvestrant (Fulv; 100 nM) or enzalutamide (Enza; 10 μM). c–d Expression of Polr2a in cells treated with or without IL-6 and varying doses of testosterone (c), or in cells treated with IL-6, testosterone, or inhibitors (d) included as a control. e–f Expression of AR (e) and Fkbp5 (f) in primary breast tumor samples from women with high or low IL-6, as profiled in GSE54430. (g–h) Expression of Cyp19a1 (g) and Esr1 (h) in MCF7 cells treated with or without IL-6, and in human breast adipose tissue (HBA). T tests determined statistical significance. *p < 0.05; **p < 0.01; ***p < 0.001